A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer

NCT07321145 · tracked via the Priya Life Science China tracker

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Phase

Not applicable

Started

2025-06-27

Last updated

2026-01-06

Condition(s) studied

Breast CancerBreast Surgery

Investigational drug(s) / intervention(s)

Robotic breast-conserving surgeryEndoscopic breast-conserving surgery

Robotic breast-conserving surgery: To perform breast-conserving surgery using a robotic system, thereby validating the safety and feasibility of robotic breast-conserving surgery.

Endoscopic breast-conserving surgery: To perform breast-conserving surgery using a endoscopic system.

Study summary

Robotic surgical systems provide notable advantages including enhanced dexterity, a magnified three-dimensional high-definition view, and high-resolution imaging, thereby improving operative stability and precision. These features make robotic systems particularly suitable for procedures performed within confined operative spaces. As the breast is a solid organ without a natural cavity, robotic systems demonstrate strong adaptability for breast surgery. Robot-assisted breast-conserving surgery (RABCS) is one of the currently utilized robotic techniques in clinical breast cancer surgery. However, as robotic breast surgery remains in its early stage of development, evidence regarding the clinical outcomes of RABCS remains limited in the literature. Therefore, this study compares the surgical outcomes of endoscopic breast-conserving surgery and robot-assisted breast-conserving surgery in breast cancer patients, aiming to assess and elucidate the clinical value of RABCS.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Female patients aged 18 to 80 years * Pathologically confirmed breast cancer prior to surgery * Sufficient glandular volume with a tumor-to-breast volume ratio ≤20% * A unifocal lesion confined to the glandular tissue * Clear desire for breast conservation and willingness to undergo R-BCS or E-BCS * No evidence of distant metastasis, no involvement of the skin or chest wall * Eligibility for standard postoperative radiotherapy Exclusion Criteria: * The presence of diffuse suspicious lesions or microcalcifications for which wide local resection was unlikely to achieve adequate negative margins or satisfactory aesthetic outcomes * Bilateral breast cancer or inflammatory breast cancer * After neoadjuvant therapy, requirement for additional concurrent surgical procedures * Inability to tolerate general anesthesia or undergo surgery * Contraindications to radiotherapy or a history of prior chest wall irradiation, pregnancy- or lactation-associated breast cancer * Refuse to undergo R-BCS or E-BCS

Primary outcome measure(s)

Postoperative complication rate — 1 month postoperatively

Trial sites (1)

Facility	City	Region	Status
the Sixth Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong	Recruiting

More Sixth Affiliated Hospital, Sun Yat-sen University trials in China

The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery Active, not recruiting

High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia Enrolling by invitation

Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer Starting soon

Prediction of Postoperative Recurrence in Crohn's Disease Recruiting

Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial Recruiting

Other trials for the same condition

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07321145 on ClinicalTrials.gov ↗ ← All trials in China